Based on a recent analysis, Mounjaro, an approved medication for Type 2 diabetes, has shown promise in reducing fat mass without significant loss of lean mass, which can improve overall body composition. In contrast, popular weight loss drugs like Wegovy and Ozempic have been found to result in the loss of lean mass instead of fat.
The data showed that during a clinical trial of tirzepatide, the active substance of Mounjaro, participants experienced a reduction of 33 to 36 percent in fat mass and 10 to 11 percent in lean mass, varying based on age group. These findings indicate that lean mass was only a quarter of the weight lost….